scholarly journals MRI-Guided Breast Biopsy-Histopathological Verification of Suspicious Breast Lesions Visible on MRI Only

2020 ◽  
Vol 7 (3) ◽  
Author(s):  
Heinze S ◽  
◽  
Rudnicki W ◽  
Popiela T ◽  
Luczynska E ◽  
...  
Keyword(s):  
Breast Biopsy ◽  
Histopathological Examination ◽  
Kinetic Curve ◽  
Breast Mri ◽  
Breast Lesions ◽  
Benign Lesions ◽  
Biopsy Site ◽  
Histopathology Result ◽  
Mri Guided ◽  
Suspicious Lesions

Background: Breast cancer is currently the most frequently diagnosed cancer in women. While the range of modalities enabling suspicious lesions detection is wide, MRI remains the most sensitive one. Therefore, the number of methods verifying the lesions seen only on MRI images grows. The aim of this study is to check the usefulness of MRI guided breast biopsy in clinical use. Methods: The study involved 120 patients who underwent diagnostic MRI before the biopsy that revealed suspicious lesions (BI-RADS 4 and 5). Those lesions had not been seen on initial ultrasonography or mammography. In each case, a marker was placed in the biopsy site and histopathological examination of the obtained samples was performed. Results: The study revealed benign lesions in 86 patients (71.7%). The remaining 34 lesions (28.3%) were determined as malignant, including 19 noninfiltrating (15.8%) and 15 infiltrating lesions (12.5%). Study showed correlation between kinetic curve type and lesion malignancy. Breast type, BPE and enhancement type did not have impact on the histopathology result. Conclusion: Breast MRI-guided biopsy is a reliable way to verify lesions not visible on any other diagnostic imaging methods and therefore should be developed.

First experience with MRI-guided vacuum aspirated breast biopsy

2020 ◽  
pp. 25-31
Author(s):  
M. L. Mazo ◽  
O. E. Jacobs ◽  
O. S. Puchkova ◽  
M. V. Feldsherov ◽  
E. V. Kondratyev
Keyword(s):  
Breast Cancer ◽  
Breast Augmentation ◽  
Breast Biopsy ◽  
Breast Mri ◽  
Breast Tumors ◽  
High Tech ◽  
X Ray ◽  
Vacuum Aspiration ◽  
Mri Guided ◽  
Aesthetic Breast

The rate of detection of breast cancer by MRI, while other methods of radiological diagnosis are not sufficiently informative, ranges from 5.2 to 26.3 per cent. Suspicious breast tumors of category BI-RADS 4, 5 show morphological image-guided biopsy verification, in particular MRI with contrast. Purpose. To show the possibilities and features of carrying out MRI-guided vacuum breast biopsy, including after aesthetic breast augmentation. Material and methods. A comprehensive X-ray, ultrasound and MRI examination of 54 women aged between 28 and 70 years with different breast tumors was conducted. Of these, five were detected only by breast MRI with contrast, and were morphologically verified by MRI-guided vacuum aspiration biopsy. Results. 14 of the 54 patients with breast mass were diagnosed with breast cancer and 26 were diagnosed with benign diseases. The effectiveness of comprehensive examination and low-invasive high-tech MRI-guided procedures in early refined screening for breast cancer, including after aesthetic breast augmentation, has been demonstrated. MRI-guided vacuum-assisted breast biopsy is a fast, safe and accurate diagnostic method of morphological verification of suspicious breast tumors that do not have X-ray and ultrasound.

Diagnostic Accuracy of Mammography and Contrast-Enhanced MR Imaging in 238 Histologically Verified Breast Lesions

1997 ◽  
Vol 38 (4) ◽  
pp. 489-496 ◽  
Author(s):  
B. Boné ◽  
Z. Péntek ◽  
L. Perbeck ◽  
B. Veress
Keyword(s):  
Mr Imaging ◽  
Breast Surgery ◽  
Histopathological Examination ◽  
High Sensitivity ◽  
Histopathological Diagnosis ◽  
Breast Lesions ◽  
Benign Lesions ◽  
Post Contrast ◽  
X Ray ◽  
Contrast Enhanced

Purpose: To determine the sensitivity and specificity of X-ray mammography and of MR imaging in 238 consecutively operated breasts, and to correlate the findings to histopathological diagnosis. Material and Methods: Over 15 months, 220 patients scheduled for breast surgery were examined consecutively, before surgery, by means of both mammography and MR imaging. of the 220 patients, 18 underwent bilateral breast surgery. The entire breast was examined by means of T1-weighted transversal images using a 3D fast low-angle shot (FLASH) sequence. One pre— and 2 post-contrast scans were performed. Each breast was examined by means of mammography and 3 views were applied as routine. All palpable and mammographically suspect lesions were examined on additional images as microfocus magnification or spot compression. The two methods were evaluated independently of each other. Results: In total, 145 malignant and 93 benign lesions were found at histopathological examination. The sensitivity of mammography was 89% and MR imaging 92%. The specificity was 72% in both methods. When the results of the 2 methods were combined, a sensitivity of 99% and a specificity of 55% was achieved. Conclusion: Mammography and MR imaging seemed to complement each other to produce a high sensitivity. Unfortunately it is impossible at present to supplement mammography with MR imaging in each patient as a routine owing to the current technical and financial limitations.

scholarly journals Enhanced MRI and MRI-Guided Interventional Procedures in Women with Asymptomatic Silicone-Injected Breasts

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Yun-Chung Cheung ◽  
Shin-Chih Chen ◽  
Yung-Feng Lo
Keyword(s):  
Breast Cancer ◽  
Breast Augmentation ◽  
Interventional Procedures ◽  
Breast Mri ◽  
Silicone Injection ◽  
Enhanced Mri ◽  
Breast Sonography ◽  
Mri Guided ◽  
Asymptomatic Women ◽  
Suspicious Lesions

Asymptomatic women who have received silicone injection for breast augmentation have a risk of underestimating breast cancer by palpation, mammography, or breast sonography. Enhanced breast MRI is sensitive to display certain nonspecific enhanced lesions or suspicious lesions. Such nonspecific MRI-detected lesions could be managed by American College Radiology BI-RADS lexicon and selectively with MRI-guided techniques biopsy to prevent unnecessary surgery.

scholarly journals Pure Fibrocystic Change Diagnosed at MRI-guided Vacuum-assisted Breast Biopsy: Imaging Features and Follow-up Outcomes

2020 ◽  
Vol 2 (2) ◽  
pp. 141-146
Author(s):  
Shu-Tian Chen ◽  
Satoko Okamoto ◽  
Bruce L Daniel ◽  
James Covelli ◽  
Wendy B DeMartini ◽  
...  
Keyword(s):  
Breast Biopsy ◽  
Breast Mri ◽  
Lesion Size ◽  
Imaging Features ◽  
Mri Features ◽  
Fibrocystic Change ◽  
Mri Guided ◽  
Lesion Regression ◽  
Mri Characteristics

Abstract Objective Fibrocystic change (FCC) is considered one of the most common benign findings in the breast and may be commonly seen on breast MRI. We performed this study to identify MRI characteristics of pure FCC on MRI-guided vacuum-assisted breast biopsy (VABB) without other associated pathologies and describe the findings on MRI follow-up and outcomes. Methods A retrospective review was performed for 598 lesions undergoing 9-gauge MRI-guided VABB at our institution from January 2015 to April 2018, identifying 49 pure FCC lesions in 43 patients. The associations between variables and lesion changes on follow-up MRI were analyzed using exact Mann-Whitney tests and Fisher’s exact tests. Results MRI features of pure FCC are predominantly clumped nonmass enhancement (19/49, 39%) or irregular masses with initial fast/late washout kinetics (9/49, 18%). There was no upgrade to high-risk or cancerous lesions among the 11 patients (25.6%) who underwent surgery. There were 22 pure FCC lesions in 19 (44.2%) patients who had follow-up MRI (mean 18.0 months, range 11–41 months) showing regression (13, 59%), stability (8, 36%), or progression (1, 5%) of the lesion size, and no cancers were found on follow-up at the site of the MRI biopsy for fibrocystic changes. No patient demographics or lesion features were associated with lesion regression or stability (P > 0.05). Conclusion Our study shows that MRI features of VABB-proven FCC lesions may mimic malignancy. After VABB of pure FCC, given that adequate sampling has been performed, a 12-month follow-up MRI may be reasonable.

Contrast enhanced spectral mammography (CESM) guided breast biopsy as an alternative to MRI guided biopsy

2022 ◽  
Author(s):  
Jonathan James
Keyword(s):  
Breast Biopsy ◽  
Lobular Carcinoma ◽  
Breast Mri ◽  
Diagnostic Study ◽  
Guided Biopsy ◽  
Iodinated Contrast ◽  
Contrast Enhanced ◽  
Multifocal Breast Cancer ◽  
Conventional Mammography ◽  
Mri Guided

Objective: Contrast Enhanced Spectral Mammography (CESM) breast biopsy has been recently introduced into clinical practice. This short communication describes the technique and potential as an alternative to MRI guided biopsy. Methods and materials: An additional abnormality was detected on a breast MRI examination in a patient with lobular carcinoma. The lesion was occult on conventional mammography, tomosynthesis and ultrasound and required histological diagnosis. Traditionally this would have necessitated a MRI guided breast biopsy, but was performed under CESM guidance. Results: A diagnostic CESM study was performed to ensure the lesion visibility with CESM and then targeted under CESM guidance. A limited diagnostic study, CESM scout and paired images for stereotactic targeting were obtained within a 10 min window following a single injection of iodinated contrast agent. The time from positioning in the biopsy device to releasing compression after biopsy and marker clip placement was 15 min. The biopsy confirmed the presence of multifocal breast cancer. Conclusion: CESM guided breast biopsy is a new technique that can be successfully used as an alternative to MRI guided breast biopsy. Advances in knowledge: CESM guided biopsy can be used to sample breast lesions which remain occult on standard mammography and ultrasound.

MRI-Guided Breast Biopsy: Influence of Choice of Vacuum Biopsy System on the Mode of Biopsy of MRI-Only Suspicious Breast Lesions

2010 ◽  
Vol 194 (6) ◽  
pp. 1650-1657 ◽  
Author(s):  
Simone Schrading ◽  
Birgit Simon ◽  
Michael Braun ◽  
Eva Wardelmann ◽  
Hans H. Schild ◽  
...  
Keyword(s):  
Breast Biopsy ◽  
Breast Lesions ◽  
Vacuum Biopsy ◽  
Mri Guided

The Role of Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Differentiating Malignant From Benign Breast Lesions Presenting Washout Curve

2020 ◽  
pp. 084653712090709
Author(s):  
Sehnaz Tezcan ◽  
Funda Ulu Ozturk ◽  
Nihal Uslu ◽  
Eda Yilmaz Akcay
Keyword(s):  
Breast Mri ◽  
Breast Lesions ◽  
Benign Lesions ◽  
Cutoff Value ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

Purpose: The aim of this study is to evaluate the diagnostic performance of combined breast magnetic resonance imaging (MRI) protocol including dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging (DWI) in patients with enhancing lesions that demonstrated washout curve and to determine whether applying apparent diffusion coefficient (ADC) cutoff value could improve the diagnostic value of breast MRI. Methods: The retrospective study included 116 patients with 116 suspicious breast lesions, which showed washout curve on DCE-MRI, who underwent subsequent biopsy. Morphologic characteristics on DCE-MRI and ADC values on DWI were evaluated. Apparent diffusion coefficient values and morphologic features of benign and malignant lesions were compared. Diagnostic values of DCE-MRI and combined MRI, including DCE-MRI and DWI (applying an ADC cutoff value) for distinguishing malignancy from benign lesions, were calculated. Results: Of the 116 breast lesions, 79 were malignant and 37 were benign. The ADC value of malignant tumors (median ADC, 0.72 × 10−3 mm2/s) was significantly lower than that of benign lesions (median ADC, 1.03 × 10−3 mm2/s; P < .000). The sensitivity and specificity of an ADC cutoff value of 0.89 × 10−3 mm2/s were 92% and 95%, respectively. Dynamic contrast-enhanced MRI alone presented 100% sensitivity and 59.4% specificity. Adding an ADC cutoff value of 0.89 × 10−3 mm2/s provided 100% sensitivity and 81% specificity, which would have prevented biopsy for 21.6% of benign lesions without missing any malignancies. Conclusion: Applying an ADC cutoff value to DCE-MRI provides an improvement in the diagnostic value of breast MRI for differentiating among lesions presenting washout curve.

MRI-Guided Core Biopsy

2018 ◽  
Author(s):  
Lisa A. Mullen
Keyword(s):  
Core Biopsy ◽  
Breast Biopsy ◽  
Breast Mri ◽  
Key Points ◽  
Mri Guided ◽  
Magnetic Resonance Imaging Mri ◽  
Extent Of Disease ◽  
Mass Enhancement ◽  
High Risk Screening

MRI-guided breast biopsy techniques were developed to sample indeterminate and suspicious breast lesions visible only on MRI. Breast MRI performed for high-risk screening, problem solving, or assessment of extent of disease in patients with newly diagnosed breast cancer may demonstrate indeterminate findings, such as enhancing foci, masses or non-mass enhancement. If the lesion is not visible by mammography or ultrasound, and MRI follow-up is not appropriate, then MRI-guided biopsy is indicated. This chapter, appearing in the section on interventions and surgical changes, reviews the key points and procedural protocols and pitfalls for performance of magnetic resonance imaging (MRI)–guided breast core biopsy. Pre-, peri-, and post-procedure clinical management, radiology–pathology correlation, and imaging follow-up are also reviewed.

Image-Guided Procedure Versus 2-year Follow-up for a BI-RADS 3 Probably Benign Lesion: A Cost Comparison Analysis

2020 ◽  
Author(s):  
Andrew Ong ◽  
Armina Azizi ◽  
Emily B Ambinder ◽  
Eniola T Oluyemi ◽  
Susan C Harvey ◽  
...  
Keyword(s):  
Breast Imaging ◽  
Breast Biopsy ◽  
Breast Mri ◽  
Cost Comparison ◽  
Average Risk ◽  
Risk Population ◽  
Image Guided ◽  
Mri Guided ◽  
Benign Biopsy

Abstract Objective Perform a comparison between the costs of image-guided breast procedures versus 2-year imaging follow-up for findings classified as BI-RADS does not need to be expanded in the abstract BI-RADS assessment category 3-probably benign. Methods The national payment amount costs at non-facility locations were obtained from the Centers for Medicare and Medicaid Services physician fee schedule for breast imaging-related Current Procedural Terminology codes. Total costs were calculated and compared for management algorithms of 2-year imaging follow-up of a BI-RADS 3 lesion from 2018 through 2019 versus performing an image-guided procedure of the lesion in 2018 after the initial diagnostic imaging. Results Two-year mammographic follow-up of a BI-RADS 3 finding costs $484. This was less than a stereotactic-guided breast biopsy, which cost at least $1055. Two-year follow-up for a probably benign ultrasound does not need to be expanded in JBI US finding cost $615 compared to $1173 for the least expensive US-guided breast biopsy scenario. For breast MRI, 2-year imaging follow-up cost $1510, which was also less than most MRI-guided breast biopsy scenarios. The one exception in which biopsy costs less than 2-year imaging follow-up was in the setting of an MRI-guided biopsy in the average-risk population without a post-benign biopsy follow-up breast MRI; in this setting, MRI biopsy cost $1235. Conclusion In 2018–2019, 2-year imaging follow-up of a BI-RADS 3 finding continues to be less costly than an immediate procedure, except for MRI-guided breast biopsy in the average-risk population without a post-benign biopsy follow-up MRI.

Sign in / Sign up

Export Citation Format

Share Document